Moors & Cabot’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
AI
Moors & Cabot's CRL Position: Q2 2026 in Review
Moors & Cabot increased its Charles River Laboratories (CRL) stake by 2% in Q2 2026, buying an estimated $6.05K and bringing the position to 1,731 shares worth $393K. The position accounts for 0.02% of the portfolio, ranked #645.
Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 20 quarters since. The position peaked at $743K in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Moors & Cabot held 1,731 shares of Charles River Laboratories worth $393K as of Q2 2026.
- Moors & Cabot bought 34 Charles River Laboratories shares in Q2 2026, an estimated $6.05K.
- Charles River Laboratories made up 0.02% of Moors & Cabot's portfolio in Q2 2026, its #645 holding.
- Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 20 quarters since.
- Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.